IFN-alpha 4 Antibody (1020125) [Alexa Fluor™ Plus 647]

• Reactivity: Mu
• Clone: 1020125
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor Plus 647

IFN-alpha 4 Antibody (1020125) [Alexa Fluor™ Plus 647] Summary

• Specificity: Detects mouse IFN-alpha 4 in direct ELISAs. In direct ELISAS, no cross-reactivity with recombinant mouse IFNA-1, -2, -6, -7, -9, -11, -12, -13, -15 or -16 is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IFN-alpha 4 Antibody (1020125) [Alexa Fluor™ Plus 647]

• IFNA4
• IFNalpha 4
• IFN-alpha 4
• IFN-alpha-4
• IFN-alpha4a
• INFA4
• interferon alpha-4
• Interferon alpha-4B
• Interferon alpha-76
• Interferon alpha-M1
• interferon, alpha 4
• MGC142200

Background

The interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, and are classified based on their binding specificity to cell surface receptors (1). The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 ( alpha -subunit) and IFNAR2 ( beta -subunit). This binding contributes to TNF-alpha induced signaling (2, 3). Both the human and mouse genome code for more than a dozen closely related IFN-alpha subtypes and the various IFN-alphas share about 80% sequence homology among them (4, 5). The mouse IFN-alpha 4 consists of 186 amino acids (aa) including a 24 aa signal peptide and a 162 aa IFN-alpha 4 mature domain. The mature mouse IFN-alpha 4 shares 58% and 76% sequence identity with mature human and rat IFN-alpha 4, respectively. The mouse IFN-alpha 4 reduces the local replication of murine cytomegalovirus in the tibia muscle (6). mIFN-A4 is a strong activator of Mx gene and  was shown to be very effective in reducing splenomegaly (7).

1. Pestka S, et al. (1987) Annu Rev Biochem. 56:727.
2. Fung, K.Y. et al. (2013) Science 339:1088.
3. Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
4. Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
5. van Pesch, V. et al. (2004) J. Virol. 78:8219.
6. Yeow, W.S. et al. (1998) J. Immunol. 15:2932.
7. Gerlach, N. et al. (2009) European J. Immunol. 39:136.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.